EXTON, Pa.--(BUSINESS WIRE)--Fibrocell Science, Inc. (NASDAQ:FCSC), an autologous cell therapy company focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs, today announced that it will host an R&D Day in New York on September 24, 2014. Presentations by key opinion leaders will include the Company’s lead orphan disease program that uses genetically-modified autologous fibroblasts—developed in collaboration with Intrexon Corporation (NYSE:XON), a leader in synthetic biology—to treat recessive dystrophic epidermolysis bullosa (RDEB), a debilitating, genetic skin disease. In addition, updates will be presented on two Phase II clinical trials for azficel-T, Fibrocell’s proprietary autologous fibroblast technology, for vocal cord scarring and restrictive burn scarring. Both studies leverage the Company’s existing BLA for azficel-T through supplemental drug applications to develop treatments for serious scarring conditions.
Help employers find you! Check out all the jobs and post your resume.
